Angiotensin converting enzyme inhibitor
Angiotensin converting enzyme inhibitor is a pharmaceutical drug with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
5 of 5 finished
0.0%
0 ended early
1
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
The COVID-RASi Trial (COVID-19)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
ARB, ACEi, DRi Effects on COVID-19 Course Disease
The Effect of Enalapril, Losartan or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients
Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease
Clinical Trials (6)
The COVID-RASi Trial (COVID-19)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
ARB, ACEi, DRi Effects on COVID-19 Course Disease
The Effect of Enalapril, Losartan or Not Antihypertensive on the Oxidative Status in Renal Transplant Recipients
Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease
Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6